Scotts Miracle-Gro names Prathima Hegde as CIO
Bitget2026/10/06 20:07Scotts Miracle-Gro named Prathima Hegde senior vice president, chief information officer. Role covers enterprise IT, technology modernization, AI integration, digital capabilities, operational excellence, SAP S/4HANA implementation. Hegde most recently served as CIO of Del Monte Foods, leading cloud modernization, data analytics, AI initiatives. Earlier roles include head of corporate applications at Tropicana Brands Group, senior IT positions at Adtalem Global Education, Abbott Laboratories. Hegde reports to President and CEO Nate Baxter as a member of the leadership team. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. The Scotts Miracle-Gro Company published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610061605PRIMZONEFULLFEED9840775) on October 06, 2026, and is solely responsible for the information contained therein.
- Scotts Miracle-Gro named Prathima Hegde senior vice president, chief information officer.
- Role covers enterprise IT, technology modernization, AI integration, digital capabilities, operational excellence, SAP S/4HANA implementation.
- Hegde most recently served as CIO of Del Monte Foods, leading cloud modernization, data analytics, AI initiatives.
- Earlier roles include head of corporate applications at Tropicana Brands Group, senior IT positions at Adtalem Global Education, Abbott Laboratories.
- Hegde reports to President and CEO Nate Baxter as a member of the leadership team.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
A $5 billion single-product emerges? JPMorgan maintains a "Neutral" rating on Amgen (AMGN.US): A good drug doesn't necessarily mean a good buying opportunity.
Amgen's Imdelltra has maintained data with an HR of 0.42, nearly doubling survival time. Morgan Stanley estimates that it will become a single product with annual sales of around 5 billions USD. However, they maintain a Neutral rating and a target price of 350 USD.
Goldman Sachs: Yen Regains "Safe Haven King" Status, Becomes Most Effective Tool to Hedge Against AI Market Shocks
Goldman Sachs stated that the Japanese yen has become a better tool for hedging against AI shocks, with policy shifts reducing the risk of depreciation. The bank recommends shorting USD/JPY and EUR/JPY.
Crypto prices
More
